Background. -Severe pulmonary hypertension is a usual contraindication to heart transplantation. A few studies have found that sildenafil has a favourable effect on haemodynamic variables in patients with severe left ventricular systolic dysfunction. Aim. -To report our clinical experience of sildenafil in patients with left ventricular systolic dysfunction and severe pulmonary hypertension. Methods. -All patients underwent echocardiography, radionuclide angiography, a cardiopulmonary exercise test and right heart catheterization before and after treatment with sildenafil. All patients were clinically stable and were receiving maximal tolerated doses of recommended drugs.
Background
Morbimortality remains elevated despite improvements in the therapeutic management of patients with heart failure related to left ventricular systolic dysfunction (LVSD) [1] [2] [3] [4] [5] . Heart transplantation is required in some patients, but the low number of heart donors is a major limiting factor preventing the widespread use of this approach. Because of this limitation, the implantation of a left ventricular assist device (LVAD) as a bridge to transplantation is sometimes required. For some young patients in whom heart transplantation is contraindicated because of non-cardiac comorbidities, a LVAD can be implanted definitively as a destination therapy. Heart transplantation or LVAD implantation are effective therapies, but with a high operative risk. Thus, the selection of candidates for these alternative therapies must be performed carefully. One major contraindication to heart transplantation is the presence of severe pulmonary hypertension [6, 7] . Currently, we do not have effective drugs that have demonstrated a significant effect on post-capillary pulmonary hypertension. Some studies in patients with post-capillary pulmonary hypertension have reported the usefulness of sildenafil, a phosphodiesterase type V inhibitor, extensively prescribed in patients with pulmonary arterial hypertension [8, 9] . We report our clinical experience with sildenafil in patients with LVSD and with severe pulmonary hypertension and elevated pulmonary vascular resistance (PVR).
Methods

Study population
We included in this analysis all patients admitted to our department between 2007 and 2013 for a possible listing for heart transplantation. All patients had chronic heart failure related to LVSD and were receiving maximal tolerated doses of recommended drugs. For angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and beta-blockers, we determined the percentage of maximal recommended doses of the different drugs, based on the most recent European guidelines [10] . Patients underwent echocardiography, radionuclide angiography, a cardiopulmonary exercise test and right heart catheterization.
Haemodynamic measurements
Right heart catheterization was performed under local anaesthesia, either by the brachial or the femoral vein, using a Swan-Ganz catheter. All measurements were obtained at steady state with the patient in a supine position. Mean pulmonary artery pressure (mPAP) and pulmonary artery wedge pressure (PAWP) were calculated by the computer as the integrated mean of the curves. Mixed central venous blood gas was sampled from the pulmonary artery. Cardiac output was determined as the mean of three to seven separate measurements by the thermodilution technique. PVR, cardiac index, transpulmonary gradient (mPAP-PAWP) and diastolic pressure gradient (diastolic pulmonary pressure -PAWP) were calculated using standard formulae. After baseline measurements, in case of elevated PVR (> 3 Wood units [WU]), dobutamine infusion was started at a dose of 10 ␥/kg/min over 10 minutes and increased up to 40 ␥/kg/min in case of insufficient response, and a complete new haemodynamic evaluation was performed.
Other measurements
Echocardiography was performed with a Vivid E9 (GE Medical Systems, Wauwatosa, WI, USA) with the determination of standard and Doppler variables according to the recommendations of the American Society of Echocardiography [11] . Left ventricular filling pressure was estimated by the sonographer (normal or increased), as recommended by the American Society of Echocardiography [12] . Equilibrium radionuclide angiography was performed at rest in the supine position for the determination of left ventricular ejection fraction and right ventricular ejection fraction, using an ECAM camera (Siemens, Erlangen, Germany), after the injection of 740 MBq of technetium-99 m. The data for gas exchange during the cardiopulmonary exercise test were collected on a breath-by-breath basis using a computerized system (Vmax; SensorMedics, Yorba Linda, CA, USA). Peak oxygen consumption was defined as the highest average value during 20 seconds, obtained during the last minute of exercise. The predicted value of maximal oxygen consumption was calculated using Wasserman's equation. B-type natriuretic peptide concentration was measured with the Advia Centaur BNP assay (Bayer Healthcare LLC, Tarrytown, NY, USA), and with the Triage BNP assay (Biosite Diagnostics, Inc., San Diego, CA, USA) for the historical cohort.
Committee decision
The decision to add patients to the waiting list for heart transplantation or to propose an LVAD implantation in young patients (≤ 65 years) with contraindication to heart transplantation was made by a committee that included cardiologists, surgeons and anaesthesiologists, all of whom were experts in heart failure. This committee estimated the operative risk for each patient and decided to introduce sildenafil when the risk was estimated to be excessive because of at least the presence of persistent post-capillary pulmonary hypertension, defined as mPAP ≥ 25 mmHg, PAWP > 15 mmHg and PVR > 3 WU, without reversibility despite an inotropic challenge with dobutamine (PVR ≥ 3 WU or mPAP ≥ 35 mmHg with a transpulmonary gradient ≥ 12 mmHg). Sildenafil was started at a dose of 20 mg three times daily. Doses were increased in case of nonfunctional improvement and a new cardiac evaluation was performed six months after the last increase in sildenafil dose.
Statistical analysis
Results are expressed as means ± standard deviations or as medians with interquartile ranges for variables that were not normally distributed. 
Results
From January 2007 to December 2013, 268 patients were admitted for possible inclusion on the waiting list for heart transplantation. The patient flow chart is presented in Fig. 1 . From these 268 patients, we included in this open-label study, 18 patients suitable for either heart transplantation or LVAD implantation, with elevated PVR and a high estimated operative risk. Baseline characteristics are presented in Table 1 . The mean age of the study population was 47 ± 13 years, there were three women, one patient had chronic atrial fibrillation and four patients had diabetes mellitus. LVSD was related to ischaemic cardiopathy in 10 patients, five patients had dilated cardiomyopathy, one had anthracycline-induced cardiopathy, one had a valvular heart disease and the last patient had a congenital cardiopathy (neonatal myocardial infarction). Five patients had complete left bundle branch block with resynchronization therapy; 17 had an implantable defibrillator. The treatment of the study population is summarized in Table 1 . All patients received maximal tolerated doses of renin inhibitors (ramipril, Figure 1 . Flow chart of the study population. HF: heart failure; LVAD: left ventricular assist device; pt: patient; PVR: pulmonary vascular resistance; RHC: right heart catheterization; Tx: transplantation; WL: waiting list for heart transplantation; WU: Wood units. Table 1 . Sildenafil improved New York Heart Association classification but not peak oxygen consumption. However, the VE/VCO 2 slope was improved, as was right ventricular ejection fraction (from 26 ± 7% to 30 ± 9%; P = 0.008). There was no significant modification in echocardiographic variables or B-type natriuretic peptide concentration. Haemodynamic data before and after sildenafil are presented in Table 2 . The median duration between the two right heart catheterizations was 8.72 (4.4-13.5) months. Fig. 2 shows the mean PVR with and without dobutamine infusion and before and after sildenafil. There was a significant decrease in PVR after sildenafil and a significant increase in cardiac index (and in venous pulmonary saturation), either at rest or during dobutamine infusion. Fig. 3 shows the individual data for the 18 patients.
Follow-up
The median follow-up period after the second right heart catheterization was 0.74 (0.28-1.56) years. Patients were censored at the time of heart transplantation or LVAD implantation. Fig. 1 shows the flow chart of the patients according to PVR after sildenafil. Three patients had UNOS1 urgent heart transplantation (one of whom died during the postoperative period), two had a successful non-urgent transplantation, six patients received an LVAD (one of whom died during the postoperative period), three patients died from heart failure and four patients improved (two of these patients were withdrawn from the waiting list for heart transplantation because of a dramatic and persistent improvement [after 4.5 and 2.5 years]).
All patients had PVR > 3 WU before sildenafil and nine patients had PVR > 3 WU after sildenafil therapy, two of whom had persistent PVR > 3 WU during dobutamine infusion. All the patients with PVR < 3 WU after sildenafil were alive, compared with four in the other subgroup (44% survival). In patients with PVR > 3 WU after sildenafil, the two patients with persistent elevated PVR during dobutamine infusion died, compared with three of the seven patients who had PVR < 3 WU during dobutamine infusion. The five patients who died had the highest PVR after sildenafil treatment (from 4.64 to 6.47 WU). One young patient (age 44 years) with PVR > 3 WU after sildenafil treatment died of multiorgan dysfunction and sepsis during the postoperative period after heart transplantation. Baseline PVR was unchanged after sildenafil treatment (5.40 to 5.66 WU). However, PVR during dobutamine infusion was lower after sildenafil (6.19 to 2.62 WU). mPAP, transpulmonary gradient and diastolic pulmonary gradient were not helpful for risk stratification of the patients. Ultimately, six patients were successfully transplanted, three patients had a definitive LVAD implantation, two patients were withdrawn from the waiting list for heart transplantation, and two improved and were still on the waiting list (72% survival). Sildenafil was well tolerated, without any complications -in particular, no systemic hypotension.
Historical cohort
The 18 patients in the study population were compared with the 18 previous patients with the same inclusion criteria seen between 1999 and 2006. The mean age of these 'historical patients' was 49 ± 8 years (P = 0.74), four were women, 11 had ischaemic cardiopathy, two patients had atrial fibrillation, five had diabetes mellitus, five had complete left bundle branch block (one of whom had resynchronization therapy) and 11 patients had an implantable defibrillator. Major clinical characteristics and the treatment of these patients are presented in Table 1 . Haemodynamic data were similar (Table 2) . After a median follow-up period of 1.46 (1.16-2.50) years, all the patients had died: six sudden cardiac deaths (three of whom had an implantable defibrillator), nine heart failure deaths, two non-cardiac-related deaths and one death after heart transplantation. By comparison, survival in our study population was 72%, with a median follow-up period starting after the first right heart catheterization of 1.34 (1.05-2.50) years (P = 0.41).
Discussion
We found a significant improvement in haemodynamic variables after sildenafil treatment, with a particularly notable decrease in PVR. The decrease in PVR was mainly related to a vasodilator effect of sildenafil in the pulmonary circulation, demonstrated by an increase in cardiac index without increase in pulmonary pressure or PAWP. All patients who had a significant response to sildenafil with a decrease in PVR < 3 WU were alive at follow-up. In the nine patients with PVR > 3 WU after sildenafil, dobutamine infusion during right heart catheterization was associated with a significant decrease in PVR in seven patients. The two patients with persistent PVR > 3 WU after dobutamine infusion died, compared with three patients who had a decrease in PVR < 3 WU. Of interest, the five patients who died had the highest PVR after sildenafil (> 4.5 WU), and four of them did not respond to sildenafil, with greater PVR after than before sildenafil treatment. Finally, we had 72% survival in a severe subgroup of patients with chronic heart failure. We cannot exclude a combined effect of sildenafil and diuretics, as doses of diuretics were modestly increased after the first right heart catheterization. However, right atrial pressures were similar before and after sildenafil, suggesting that the increase in the doses of diuretics had minimal effects on pulmonary and cardiac haemodynamics. Another possible therapeutic option in patients with severe chronic heart failure is to reduce doses of beta-blockers in order to increase heart rate and cardiac index. However, no study has examined this alternative therapeutic option. Moreover, a recent analysis in patients with pulmonary arterial hypertension failed to demonstrate a harmful effect of beta-blocker therapy [13] .
Other previous studies looking at the chronic effect of sildenafil in patients with severe LVSD were small studies, from case reports to studies that included no more than 31 patients [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . The main results of these studies are summarized in Table 3 ; they were all open-label, except for the study by Lewis et al. [16] . All of these studies demonstrated significant and favourable effects on haemodynamic variables, which were translated into clinical improvement in most cases. In the study by Lewis et al., 34 patients were randomized to 12 weeks of treatment with sildenafil or placebo. Sildenafil was associated with a significant decrease in PVR at rest and during exercise compared with placebo, with a significant increase in both cardiac output during exercise and exercise capacity. Sildenafil also improved right ventricular ejection fraction. Other studies in patients with persistent pulmonary hypertension after LVAD implantation have found a significant decrease in pulmonary pressures with sildenafil therapy [24] . Several double-blind placebo-controlled trials in patients with chronic heart failure, but without haemodynamic inclusion criteria, have analysed chronic administration (up to one year) in fewer than 55 patients with chronic heart failure. In these studies, sildenafil demonstrated a significant increase in exercise capacity and favourable effects on cardiac remodelling [25, 26] . However, in a recent double-blind, placebo-controlled study in patients with heart failure with preserved ejection fraction, sildenafil failed to demonstrate any significant effect on exercise capacity [27] . In our study, except for New York Heart Association functional classification, VE/VCO 2 slope and right ventricular ejection fraction, we did not find any significant modification to any other variable after sildenafil. This is not surprising, because our patients had very severe heart failure and because the time between the two evaluations was short.
We compared our study population with a 'historical' cohort. There were some minor clinical differences but the haemodynamic data were similar. However, we did not control right heart catheterization in the 'historical' patients. Thus, we do not have the natural evolution of haemodynamic data. It is very difficult to compare survival in these two populations because the therapeutic management has changed. The percentage of patients with implantable defibrillators was lower in the 'historical' cohort compared with in the study population, explaining the high rate of sudden cardiac-related death. Moreover, an LVAD was not routinely implanted as a destination therapy. All patients from our 'historical' cohort died during a short follow-up period (1.13 [0.36-2.67] years) compared with 28% in our study population (1.46 [1.1-2.67] years).
Sildenafil is extensively prescribed in patients with pulmonary arterial hypertension. Currently, in patients with post-capillary pulmonary hypertension, we are starting sildenafil only in those selected for heart transplantation or before LVAD implantation in case of contraindication to heart transplantation. We do not have any data concerning the long-term safety of sildenafil in patients with LVSD, and we discourage the off-label prescription of sildenafil in other subgroups of patients with chronic heart failure.
Study limitations
The major limitation of the present study was that it was not placebo-controlled. As in previous studies, we report our clinical experience in a very specific subgroup of patients -young heart transplant candidates with severe pulmonary hypertension. However, all patients underwent the same protocol before and after the introduction of sildenafil and, particularly, the same haemodynamic evaluation.
Conclusion
In this open-label study in patients with severe LVSD and pulmonary hypertension, sildenafil was associated with a significant decrease in PVR. Survival was better in patients who had a decrease in PVR with sildenafil. Further studies are required, particularly a double-blind placebo-controlled trial, to determine exactly the effects of sildenafil in patients with severe chronic heart failure.
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